Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Relieving Opioid-Induced Constipation (OIC) in Patients With Cancer-Related Pain
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Naloxegol (Primary)
- Indications Constipation
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 05 Oct 2021 This trial has been completed in Spain (End Date: 20 Sep 2012), according to European Clinical Trials Database record.
- 29 May 2015 Status changed from completed to discontinued as per ClinicalTrials.gov record.
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.